Xenon Pharmaceuticals Inc. (NASDAQ:XENE) At $31.96: What To Do? – Marketing Sentinel
Home  »  Technologies   »  Xenon Pharmaceuticals Inc. (NASDAQ:XENE) At $31.96...

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) At $31.96: What To Do?

In last trading session, Xenon Pharmaceuticals Inc. (NASDAQ:XENE) saw 0.67 million shares changing hands with its beta currently measuring 1.90. Company’s recent per share price level of $31.96 trading at $2.83 or 9.72% at ring of the bell on the day assigns it a market valuation of $1.68B. That closing price of XENE’s stock is at a discount of -13.95% from its 52-week high price of $36.42 and is indicating a premium of 56.26% from its 52-week low price of $13.98. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.46 million shares which gives us an average trading volume of 548.41K if we extend that period to 3-months.

For Xenon Pharmaceuticals Inc. (XENE), analysts’ consensus is at an average recommendation of a Buy while assigning it a mean rating of 1.40. Splitting up the data highlights that, out of 9 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 9 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -$0.34 in the current quarter.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


Xenon Pharmaceuticals Inc. (NASDAQ:XENE) trade information

Upright in the green during last session for gaining 9.72%, in the last five days XENE remained trading in the green while hitting it’s week-highest on Friday, 01/14/22 when the stock touched $31.96 price level, adding 0.68% to its value on the day. Xenon Pharmaceuticals Inc.’s shares saw a change of 2.30% in year-to-date performance and have moved 4.79% in past 5-day. Xenon Pharmaceuticals Inc. (NASDAQ:XENE) showed a performance of 20.29% in past 30-days. Number of shares sold short was 2.12 million shares which calculate 3.87 days to cover the short interests.

Xenon Pharmaceuticals Inc. (XENE) estimates and forecasts

Statistics highlight that Xenon Pharmaceuticals Inc. is scoring comparatively lower than the scores of other players of the relevant industry. The company added 78.85% of value to its shares in past 6 months, showing an annual growth rate of -111.11% while that of industry is 7.90. Apart from that, the company came lowering its revenue forecast for fiscal year 2022. The company is estimating its revenue growth to decrease by -36.00% in the current quarter and calculating -4.80% decrease in the next quarter. This year revenue growth is estimated to fall -27.90% from the last financial year’s standing.

8 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $6.42 million for the same. And 4 analysts are in estimates of company making revenue of $2.25 million in the next quarter that will end on Mar 2022. Company posted $5.15 million and $4.36 million of sales in current and next quarters respectively a year earlier. Analysts are expecting this quarter sales to grow by 24.70% while estimating it to be -48.40% for the next quarter.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 6.00% during past 5 years.

XENE Dividends

Xenon Pharmaceuticals Inc. is more likely to be releasing its next quarterly report between February 28 and March 04 and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.

Xenon Pharmaceuticals Inc. (NASDAQ:XENE)’s Major holders

Insiders are in possession of 2.27% of company’s total shares while institution are holding 70.44 percent of that, with stock having share float percentage of 72.08%. Investors also watch the number of corporate investors in a company very closely, which is 70.44% institutions for Xenon Pharmaceuticals Inc. that are currently holding shares of the company. Avoro Capital Advisors LLC is the top institutional holder at XENE for having 3.65 million shares of worth $55.77 million. And as of Sep 29, 2021, it was holding 7.08% of the company’s outstanding shares.

The second largest institutional holder is FMR, LLC, which was holding about 3.06 million shares on Sep 29, 2021. The number of shares represents firm’s hold over 5.93% of outstanding shares, having a total worth of $46.71 million.

>> 7 Top Picks for the Post-Pandemic Economy <<

On the other hand, Smallcap World Fund and Lord Abbett Developing Growth Fund are the top two Mutual Funds which own company’s shares. As of Sep 29, 2021, the former fund manager was holding 2.02 million shares of worth $30.85 million or 3.91% of the total outstanding shares. The later fund manager was in possession of 0.98 million shares on Oct 30, 2021, making its stake of worth around $30.6 million in the company or a holder of 1.90% of company’s stock.

Leave a Comment

Your email address will not be published. Required fields are marked *

On Key

Related Posts



Download Free eBook For



100% free. stop anytime no spam